Dr. Grant Hatch
Grant M. Hatch, PhD 
Professor - Departments of Pharmacology and Therapeutics & Biochemistry and Medical Genetics
Canada Research Chair in Molecular Cardiolipin Metabolism
Director of the  Centre for Research and Treatment of Atherosclerosis
Scientist, Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme
501C John Bhuler Research Center
715 McDermot Avenue, Winnipeg, MB R3E 3P4
(204) 789-3405  



Research Focus:
My research interests focus upon three main areas in whole animal, organ, cellular and molecular biology.

Area 1. Biology of Cardiolipin and its role in heart failure
In my research program we are examining the regulation of the metabolism of the mitochondrial polyglycerophospholipid bis-(1,2-diacyl-sn-glycero-3-phospho)-1',3'-sn-glycerol (or cardiolipin). Cardiolipin comprises approximately 20% of the entire phospholipid phosphorus composition of the heart, the highest of all mammalian tissues. Cardiolipin is required to support generation of mitochondrial energy production. Heart failure is a disease condition in which the amount and type of cardiolipin are altered and this may contribute to defective mitochondrial energy metabolism leading to cardiomyopathy and heart failure. Since alterations in cardiolipin metabolism contribute to the development of heart failure, we are examining whether restoring cardiolipin levels may represent a target for pharmacotherapeutic modulation of heart failure.

Area 2. Biology of Human Lipid Disorders
Barth Syndrome is a rare X-linked genetic disorder in young boys and is the only known genetic disease in which the specific biochemical defect is a reduction in cardiolipin (CL) and an accumulation of monolysoCL. The disease is caused by mutations in the TAZ gene. Although over 100 mutations in TAZ have been described in patients, no single mutation is concordant with the disease. A reduced ability to remodel CL is the underlying molecular mechanism responsible for the Barth Syndrome. The role that TAZ plays in CL metabolism and Barth Syndrome is an active area of investigation in the laboratory.
Type 2 diabetes and obesity have become major health concerns over the past twenty years. The role that CL plays in the development of diabetes and obesity is an active area of investigation in the laboratory. In addition, we are examining the role of nutritional interventions in the management of these disorders.

Area 3. Biology of the Blood Brain Barrier
The blood-brain barrier formed by the brain capillary endothelial cells provides a protective barrier between the systemic blood and the extracellular environment of the central nervous system. We are examining the mechanisms that govern transport across primary human brain microvessel endothelial cells (HBMEC).

Publications: PubMed

More information on Dr. Grant Hatch can be found at www.chrim.ca/researcher/grant-hatch/










Dr. Grant M. Hatch
Area of research:  Lipid metabolism, Cardiolipin

Newest Awards:
National Sciences and Engineering Research Council Discovery Grant (2019-2024)
Heart and Stroke Foundation of Canada Operating Grant (2017-2020)
Canada Research Chair in Molecular Cardiolipin Metabolism (2013-2020)